(S,R,S)-AHPC-CO-C2-ACID

Background Introduction

(S,R,S)-AHPC-CO-C2-ACID is a specialized E3 ligase ligand-linker conjugate, designed for use in targeted protein degradation technologies such as PROTACs (Proteolysis Targeting Chimeras). This compound features the AHPC moiety—an optimized ligand for recruiting the von Hippel-Lindau (VHL) E3 ubiquitin ligase system—connected via a specific linker structure. E3 ligase ligands play a pivotal role in the design of innovative therapeutic agents by enabling targeted protein degradation, a rapidly emerging strategy in drug discovery.

Mechanism

(S,R,S)-AHPC-CO-C2-ACID functions by binding to the VHL E3 ubiquitin ligase through its AHPC component. When incorporated into a bifunctional PROTAC molecule, this ligand-linker moiety connects to a warhead that recognizes the target protein. The conjugate brings the target protein in close proximity to the E3 ubiquitin ligase, catalyzing ubiquitination of the target and ultimately directing it for proteasomal degradation. The C2 linker provides optimal spatial arrangement, enhancing the efficacy and selectivity of the resulting PROTAC molecules.

Applications

(S,R,S)-AHPC-CO-C2-ACID is widely used in the design and synthesis of VHL-based PROTACs for chemical biology research and early-stage drug discovery. Its applications include development of novel therapeutics against undruggable proteins, validation of new drug targets, and creation of cell-based protein degradation assays. Researchers utilize this ligand-linker conjugate to engineer potent and selective PROTACs tailored for oncology, neurodegeneration, and immune-related diseases, accelerating the pathway from bench to bedside.

The (S,R,S)-AHPC-CO-C2-ACID is an innovative E3 Ligase Ligand-Linker Conjugate designed to optimize PROTACs for targeted protein degradation. This molecule facilitates efficient ubiquitination by bridging E3 ligases and target proteins, enhancing selectivity and potency. The following provides a detailed description of this molecule.

Linker: This conjugate features a short, flexible linker, approximately two carbon atoms in length, which provides optimal spacing between the ligand and the reactive site. Its non-cleavable nature ensures stability, maintaining the integrity of the PROTAC complex during cellular processes.

Ligand: The ligand in this molecule is an AHPC derivative, known for its high affinity and specificity towards the cereblon E3 ligase. Its stereochemistry is carefully configured to enhance binding interactions, ensuring robust recruitment of the E3 ligase to the target protein.

Reactive Site: The reactive site of this molecule is characterized by a carboxylic acid moiety, which is well-suited for coupling with amine-containing target protein ligands. Recommended reaction types include amide bond formation through EDC or HATU-mediated coupling, facilitating stable and efficient conjugation.

Recommended Target Protein Ligand: The ideal warhead for this conjugate is an amine-functionalized small molecule that can form a stable amide linkage with the reactive site. This configuration enhances the specificity and efficacy of the PROTAC, enabling precise degradation of target proteins. Applications include studying protein function and validating therapeutic targets in cellular models.